Master protocol of two independent, randomized, double-blind, Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis - EFC17919

Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 1,639 人开始时间: 2024年1月8日最近更新: 2024年7月22日

研究概览

暂无简介。

•The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria., The participant has an EDSS score =5.5 at the first visit (Screening Visit), The participant must have at least 1 of the following prior to screening: ? =1 documented relapse within the previous year OR ? =2 documented relapses within the previous 2 years, OR ? =1 documented Gd enhancing lesion on an MRI scan within the previous year., Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

•The participant has been diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria, The participant has a history of infection or may be at risk for infection., The presence of psychiatric disturbance or substance abuse., History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment., History or current hypogammaglobulinemia defined by values below the lower limit of normal (LLN)., A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren’s syndrome, acute disseminated encephalomyelitis, and myasthenia gravis., The participant has had a relapse in the 30 days prior to randomization., The participant has contraindication for MRI, ie, presence of pacemaker, metallic implants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips), presence of metallic material (eg, shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol scheduled MRI scans.

发起方

Sanofi-Aventis Recherche & Developpement